Photo: Shutterstock

Big Phar­ma is rich. So much so, their cof­fers could buy more than 600 biotechs

The pan­dem­ic made Big Phar­ma even rich­er than be­fore as vac­cines and ther­a­peu­tics splashed on­to the mar­ket to the tune of bil­lions of dol­lars. In the sopho­more year of the pan­dem­ic, a boom in biotech in­ter­est fu­eled a rise in VC fund­ing and a pre­clin­i­cal IPO flur­ry.

But the start­up world was hit hard, as many ear­ly-stage biotechs have fal­tered and faced an un­re­lent­ing bear mar­ket in re­cent quar­ters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.